Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Navigating the Supply-Chain Impacts of US Port Closings

By
The shutdown of ports on the US Gulf and East Coasts this week due to a labor strike had the potential for a major impact on the flow of US chemical shipments. With a strike now temporarily diverted, how would have chemical and pharma ingredient supply chains been affected?

Bio/Pharma Watchlist: Small-Molecule Drugs

By
Specialty small-molecule drugs are growing more than twice as fast as those of traditional small-molecule drugs. What are some key drugs contributing to this growth, and how is product innovation faring?

Pharma’s Innovations in Green Chemistry

By
As bio/pharma companies and their suppliers seek ways to improve their carbon footprint and meet sustainability targets, what have been recent noteworthy advances in green chemistry in small-molecule drug synthesis?

Generics Outlook: Small Molecules and Biosimilars

By
Small-molecule drugs dominate the global generics market, but biosimilars’ projected growth rate is double that of small-molecule drugs. Near-term projections and analysis of the generics and biosimilars market.